Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksOptiBiotix Health Share News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: -1.25 (-6.58%)
Spread: 0.50 (2.857%)
Open: 18.25
High: 17.75
Low: 17.50
Prev. Close: 19.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Safestyle suffers amid "difficult" trading conditions

Wed, 27th Sep 2023 13:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Safestyle UK PLC - Bradford-based retailer and manufacturer of PVCu replacement windows and doors - Revenue in half-year ended July 2 declines 5.3% on-year to GBP74.1 million from GBP78.3 million. Pretax loss widens to GBP6.7 million from GBP2.8 million. Decides against interim dividend, after 0.4 pence per share payout a year prior. "The trading context of the UK economy and consumer confidence remains extremely difficult. Encouragingly, inflation is beginning to show some signs of moderating, but that follows a period of sustained high inflation. The impact of significantly higher interest rates than expected is clearly impacting consumers' disposable income," Safestyle says.

----------

Zegona Communications PLC - London-based company focused on communications and entertainment opportunities - Pretax loss in six months to June narrows slightly to EUR1.8 million from EUR1.9 million. Generates no revenue, unchanged year-on-year. Zegona adds: "Over the last 6 months we have continued to focus on identifying and pursuing the right opportunity within the European telecommunications market where we can again successfully apply our proven "buy-fix-sell" strategy to generate attractive returns for our shareholders. We remain patient and disciplined in our approach and are encouraged by the stabilisation in both the economic outlook and telecommunications market trends, which contribute to the confidence we have in our ability to find the right next investment for Zegona." On Friday, it confirmed it was in talks with Vodafone Group PLC to acquire its Spanish operations. Zegona said the deal remains subject to agreement on final terms with Vodafone, completion of its due diligence and formalisation of funding arrangements. As a result, it stressed that there is "no certainty" that the potential acquisition will go ahead, nor as to any of the final terms if a deal were to be struck.

----------

ProBiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Pretax loss in six months to June 30 widens to GBP512,000 from GBP251,000 a year prior. It reports "other administrative costs" more than double to GBP668,000 from GBP274,000. Revenue rises 83% to GBP552,000 from GBP302,000. Chief Executive Officer Steen Andersen says: "Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a GBP10 million plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the company and remain committed to providing long term value to our shareholders."

----------

OptiBiotix Health PLC - York, England-based life sciences company, which develops edible compounds to tackle chronic conditions like obesity and diabetes - Swings to pretax loss of GBP1.9 million in first six months of 2023, from profit of GBP13.9 million a year prior. In the prior year, it booked a GBP21.6 million profit on the disposal of a subsidiary. It registers no such gains this time around. Revenue rises to GBP351,000 from GBP119,000. CEO Stephen O'Hara says: "The aim for the second half of the year is to maintain our focus on managing costs, growing sales and closing out ongoing discussions with a number of larger partners across first and second-generation products to ensure a return on investment from the expansion of our commercial and business development teams."

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Revenue in year ended June 30 falls 16% to GBP61.0 million from GBP72.8 million. Allergy's pretax loss stretches to GBP49.8 million from GBP12.7 million. "This financial year has been challenging, however, the group has made good progress in recovering manufacturing capacity and developing robust quality systems that are well-placed to support future growth," CEO Manuel Llobet says.

----------

Fadel Partners Inc - media rights and royalty management software developer - Revenue in half-year ended June 30 declines 20% to USD5.4 million from USD6.7 million a year earlier. Pretax loss widens to USD1.3 million from USD1.1 million. CEO Tarek Fadel says: "The outlook for Fadel remains positive and the benefits of our investments are already coming through as the strong trading momentum enjoyed in 1H23 continues into the second half of the year. Investments made in the business to date, alongside the wider shift towards digitisation, are driving increased demand for our offering and give great confidence in the group's outlook."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Feb 2020 09:09

OptiBiotix Health signs North American distribution agreement for LPLDL

(Sharecast News) - Life sciences business OptiBiotix Health has inked a distribution agreement with Advanced NutriSolutions/Select Ingredient for the exclusive sale of its patented probiotic strain LPLDL in the United States and Canada.

Read more
12 Feb 2020 10:40

OptiBiotix Health Inks Licencing Deal For Yoghurt With LPLDL Probiotic

OptiBiotix Health Inks Licencing Deal For Yoghurt With LPLDL Probiotic

Read more
12 Feb 2020 09:11

OptiBiotix strikes deal for proprietary probiotic yoghurt

(Sharecast News) - Life sciences business OptiBiotix Health announced on Wednesday that its wholly-owned subsidiary ProBiotix Health has signed a licencing agreement with Granja Pocha for the inclusion of its patented probiotic strain, 'LPLDL', into a functional yoghurt product in Uruguay.

Read more
31 Jan 2020 15:29

OptiBiotix, Agropur Launch SlimBiome Product In North America

OptiBiotix, Agropur Launch SlimBiome Product In North America

Read more
31 Jan 2020 08:57

OptiBiotix and partner Agropur launch 'SlimBiome' in North America

(Sharecast News) - Life sciences company OptiBiotix Health and its partner Agropur announced the launch of 'SlimBiome' in the North American market on Friday.

Read more
28 Jan 2020 13:02

OptiBiotix Health Expands SlimBiome And GoFigure Distribution Deals

OptiBiotix Health Expands SlimBiome And GoFigure Distribution Deals

Read more
27 Jan 2020 09:50

AlfaSigma To Launch New Supplement Containing OptiBiotix Probiotic

AlfaSigma To Launch New Supplement Containing OptiBiotix Probiotic

Read more
17 Jan 2020 10:32

OptiBiotix Health Aims For Profit In 2020; Explores Nasdaq Listing

OptiBiotix Health Aims For Profit In 2020; Explores Nasdaq Listing

Read more
17 Jan 2020 08:08

OptiBiotix eyes profitability in 2020, explores Nasdaq listing

(Sharecast News) - Life sciences business OptiBiotix Health provided revenue guidance for its recently wrapped up trading year on Friday and told investors it was now eyeing up a dual-listing on the New York Stock Exchange as it forecast profitability in 2020.

Read more
8 Jan 2020 15:56

OptiBiotix Health reports successful results from hypertension study

(Sharecast News) - Life sciences business OptiBiotix Health announced on Wednesday that its fully-owned subsidiary ProBiotix Health, in partnership with Nutrilinea, has completed a successful human study for a new food supplement formulation containing 'LPLDL', and showed that the product could reduce high blood pressure, or hypertension.

Read more
8 Jan 2020 10:42

OptiBiotix Health's LPLDL Product Reduces Hypertension In Study

OptiBiotix Health's LPLDL Product Reduces Hypertension In Study

Read more
7 Jan 2020 08:58

Holland & Barrett Launching Product Containing OptiBiotix's SlimBiome

Holland & Barrett Launching Product Containing OptiBiotix's SlimBiome

Read more
19 Dec 2019 12:25

OptiBiotix Inks New SlimBiome Distribution Deal In Germany

OptiBiotix Inks New SlimBiome Distribution Deal In Germany

Read more
17 Dec 2019 13:44

OptiBiotix Health launches two products with partners in India

(Sharecast News) - Life sciences company OptiBiotix Health announced the commercial launch of two products formulated with its 'SlimBiome' product in the Indian market on Tuesday, in partnership with Anthem BioPharma and Zeon Life Sciences.

Read more
17 Dec 2019 12:25

OptiBiotix Health Launches Two SlimBiome-Based Products In India

OptiBiotix Health Launches Two SlimBiome-Based Products In India

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.